不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫大 B 细胞淋巴瘤的免疫治疗：当前格局与未来方向
英文原题：Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions.
查看英文原题
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫性大B细胞淋巴瘤（DLBCL）是一种异质性疾病。B细胞受体（BCR）通路对恶性B细胞的生长、存活和增殖至关重要。肿瘤微环境（TME）中的T细胞和巨噬细胞等多种免疫细胞，会促进肿瘤细胞存活并参与化疗耐药。恶性B细胞及TME中存在众多靶点，推动了新型治疗药物的出现。干细胞移植是DLBCL中最早利用免疫系统的治疗手段，之后靶向CD20的单克隆抗体和嵌合抗原受体（CAR）T细胞疗法改变了DLBCL治疗格局。近期，多种新型免疫治疗药物已加入DLBCL治疗手段，且仍有许多药物在研发中。本文综述DLBCL免疫治疗的最新进展。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. B-cell receptor (BCR) pathway is essential for malignant B-cell growth, survival, and proliferation. Various immune cells, including T-cells and macrophages in the tumor microenvironment (TME) contribute to tumor cell survival and pathogenesis of chemo-resistance. The presence of many targets on the malignant B-cells and in the TME has led to emergence of novel therapeutic agents.
Stem cell transplant is the oldest treatment modality leveraging immune system in DLBCL. Subsequently, CD20 targeting monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy changed the treatment landscape of DLBCL. Recently, multiple novel immunotherapeutic agents have been added in the armamentarium for the management of DLBCL, and many are under development. In this review article, we will review latest updates of immunotherapeutic agents in the management of DLBCL.
论文信息
- 作者
- Modi D、Potugari B、Uberti J
- 单位
- Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, 4100 John R, HW04HO, Detroit, MI 48201, USA.United States
- 文献类型
- 综述
- 期刊
- Cancers2021 Nov 20
- 原文标识
- PubMed 34830980 · DOI 10.3390/cancers13225827
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →